The prevalence of HRR alterations in prostate cancer is approximately 25%; however, understanding of prognostic and therapeutic implications of different HRR alterations beyond BRCA1/2 is currently limited due to small patient cohorts. Here, BRCA1 is linked to Familial prostate cancer.